Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Oct 27, 2014; 6(10): 688-695
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.688
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.688
Table 2 Summary of potential molecular targets and novel targeted therapies for alcoholic hepatitis
Key element of the pathogenesis | Treatment | Effect | Clinical trial |
FXR dysregulation | OCA[67] | FXR agonist | Moderately severe AH (placebo vs OCA) |
Altered gut integrity | Zinc[68] | Restoration of gut integrity | Severe AH |
LGG[69] | Probiotic effect | Mild to moderate AH (placebo vs LGG) | |
Rifaximin[70] | Intestinal decontamination | Severe AH (steroid vs steroid + rifaximin) | |
Innate immune activation | Imm 12-E[71] | Anti-LPS antibody | Severe AH (steroid vs steroid + low/high dose Imm 12-E) |
Anakinra[57,58,72] | IL-1RA | Severe AH (steroid vs anakinra + pentoxifylline + zinc) | |
Rilonacept[57,58] | IL-1 inhibitor | Severe AH with response to steroid at day 7 (steroid vs steroid + rilonacept) | |
Mycophenolate mofetil | IMPDH inhibitor | Severe AH without response to steroid at day 7 (standard of care vs steroid + mycophenolate) | |
Sterile necrosis and apoptosis | Emricasan[54] | Pancaspase inhibitor | Severe AH with steroid contraindications (placebo vs emricasan) |
Impaired regeneration | G-CSF[63,64] | HPC mobilization | Severe AH without response to steroid at day 7 (placebo vs G-CSF) |
IL-22[59,73,74] | Hepatoprotective effect | Only preclinical studies |
- Citation: Kim W, Kim DJ. Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World J Hepatol 2014; 6(10): 688-695
- URL: https://www.wjgnet.com/1948-5182/full/v6/i10/688.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i10.688